Psilocybin Therapy Market Analysis, Size, Share & Growth Forecast 2026–2034

COMP360 Phase IIb 29 Percent Response and 20 Percent Remission at 3 Weeks in 25 mg Single-Dose TRD Group Versus 9 Percent Placebo Has Provided the Pivotal Efficacy Evidence That Forms the Basis for the Compass Pathways NDA Submission and the Phase III Confirmatory Programme.COMPASS Pathways's COMP360 synthetic psilocybin demonstrated 29% clinical response rate at 3 months with 25 mg dose versus 9% for 1 mg control in COMP001 Phase 2b in 233 TRD patients, providing the clinical signal that supported a USD 350 million fundraise and Phase 3 programme initiation in 2024. The Phase 3 programme tests COMP360 25 mg in 2-3 sessions with psychological support versus active control across 20-plus countries, with primary endpoints of 12-week MADRS reduction designed to generate the definitive regulatory dataset that FDA and EMA require for a Breakthrough Therapy Designation programme. The Phase 3 execution challenge involves maintaining double-blind conditions when the psychoactive effects of psilocybin are obvious to participants, and COMPASS is using niacin as an active placebo that produces flush but no psychedelic effect in the comparison arm.

Psilocybin End-of-Life Anxiety NYU and Johns Hopkins Studies Demonstrating 40 to 80 Percent Anxiety and Depression Decrease at 6 Months After Single Session Has Built the Evidence Base for the Palliative Care Indication That Compassionate Access Has Provided Pending the Clinical Approval.Oregon Measure 109's implementation through Oregon Health Authority licensing of psilocybin service centres, facilitators, and manufacturers has established a state-legal public-health model that enables supervised psilocybin administration for wellness purposes without a medical diagnosis or physician prescription. The programme's first year of operation in 2024 saw approximately 100 licensed service centres and over 3,000 psilocybin sessions, generating early data on adverse events, healthcare utilisation, and wellbeing outcomes that will inform evaluation of whether the public-health model achieves meaningful benefit without triggering the harms that drug policy advocates predicted. The regulatory tension between Oregon's state-legal programme and DEA Schedule I federal classification creates legal uncertainty for facilities and facilitators, and the Colorado Natural Medicine Health Act's similar regulatory framework enacted in 2022 has created a second state-level precedent that may accelerate federal scheduling reconsideration.

Psilocybin Schedule I DEA Classification Requiring Administrative Rescheduling After FDA Approval Through the DEA Process That the Controlled Substances Act Assigns to the Attorney General Has Established the Regulatory Pathway That the First Psychedelic-Assisted Therapy NDA Must Navigate for Commercialisation.MAPS PBC's model for MDMA-assisted therapy and COMPASS Pathways's COMP360 protocol both require trained facilitators present during 6-8-hour sessions and integration therapy in the days following each psychedelic session, creating a high-contact therapy model that significantly increases total treatment cost beyond the drug acquisition price. The facilitator training requirements create a workforce development challenge that academic medical centres, nursing organisations, and for-profit training companies are addressing through structured curricula, and the first cohorts of psilocybin-trained therapists are completing certification programmes that will staff approved therapy programmes when regulatory approval is achieved. Virtual reality integration during psilocybin sessions is being investigated by Mindstate Design Labs and others as a way to standardise and optimise the psychedelic experience through curated visual environments that are hypothesised to amplify therapeutic benefit and reduce the variability associated with the uncontrolled set-and-setting of early psilocybin therapy.

For related market intelligence, see the Depression Drug Market.